Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2024

Open Access 01-12-2024 | Acute Respiratory Distress-Syndrome | Research

Using a targeted metabolomics approach to explore differences in ARDS associated with COVID-19 compared to ARDS caused by H1N1 influenza and bacterial pneumonia

Authors: Chel Hee Lee, Mohammad M. Banoei, Mariam Ansari, Matthew P. Cheng, Francois Lamontagne, Donald Griesdale, David E. Lasry, Koray Demir, Vinay Dhingra, Karen C. Tran, Terry Lee, Kevin Burns, David Sweet, John Marshall, Arthur Slutsky, Srinivas Murthy, Joel Singer, David M. Patrick, Todd C. Lee, John H. Boyd, Keith R. Walley, Robert Fowler, Greg Haljan, Donald C. Vinh, Alison Mcgeer, David Maslove, Puneet Mann, Kathryn Donohoe, Geraldine Hernandez, Genevieve Rocheleau, Uriel Trahtemberg, Anand Kumar, Ma Lou, Claudia dos Santos, Andrew Baker, James A. Russell, Brent W. Winston, for the *ARBs CORONA I. Investigators

Published in: Critical Care | Issue 1/2024

Login to get access

Abstract

Rationale

Acute respiratory distress syndrome (ARDS) is a life-threatening critical care syndrome commonly associated with infections such as COVID-19, influenza, and bacterial pneumonia. Ongoing research aims to improve our understanding of ARDS, including its molecular mechanisms, individualized treatment options, and potential interventions to reduce inflammation and promote lung repair.

Objective

To map and compare metabolic phenotypes of different infectious causes of ARDS to better understand the metabolic pathways involved in the underlying pathogenesis.

Methods

We analyzed metabolic phenotypes of 3 ARDS cohorts caused by COVID-19, H1N1 influenza, and bacterial pneumonia compared to non-ARDS COVID-19-infected patients and ICU-ventilated controls. Targeted metabolomics was performed on plasma samples from a total of 150 patients using quantitative LC–MS/MS and DI-MS/MS analytical platforms.

Results

Distinct metabolic phenotypes were detected between different infectious causes of ARDS. There were metabolomics differences between ARDSs associated with COVID-19 and H1N1, which include metabolic pathways involving taurine and hypotaurine, pyruvate, TCA cycle metabolites, lysine, and glycerophospholipids. ARDSs associated with bacterial pneumonia and COVID-19 differed in the metabolism of D-glutamine and D-glutamate, arginine, proline, histidine, and pyruvate. The metabolic profile of COVID-19 ARDS (C19/A) patients admitted to the ICU differed from COVID-19 pneumonia (C19/P) patients who were not admitted to the ICU in metabolisms of phenylalanine, tryptophan, lysine, and tyrosine. Metabolomics analysis revealed significant differences between C19/A, H1N1/A, and PNA/A vs ICU-ventilated controls, reflecting potentially different disease mechanisms.

Conclusion

Different metabolic phenotypes characterize ARDS associated with different viral and bacterial infections.
Appendix
Available only for authorised users
Literature
1.
Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine. 2010;28(31):4895–902.PubMedCrossRef
2.
Matrosovich M, Herrler G, Klenk HD. Sialic acid receptors of viruses. Top Curr Chem. 2015;367:1–28.PubMed
3.
Turner AJ. ACE2 Cell Biology, Regulation, and Physiological Functions. The Protective Arm of the Renin Angiotensin System (RAS). 2015:185–9.
4.
Somers VK, Kara T, Xie J. Progressive hypoxia: a pivotal pathophysiologic mechanism of COVID-19 pneumonia. Mayo Clin Proc. 2020;95(11):2339–42.PubMedCrossRef
5.
Burns KCMLTMASDTKLTMSBJSJWKPDLFMJHGF. Sustained Dysregulation of the Plasma Renin-angiotensin System in Acute COVID-19. 2021.
6.
Liu X, Yang N, Tang J, Liu S, Luo D, Duan Q, et al. Downregulation of angiotensin-converting enzyme 2 by the neuraminidase protein of influenza A (H1N1) virus. Virus Res. 2014;185:64–71.PubMedCrossRef
7.
Kalil AC, Thomas PG. Influenza virus-related critical illness: pathophysiology and epidemiology. Crit Care (Lond, Engl). 2019;23(1):258.CrossRef
8.
Metwaly S, Côté A, Donnelly SJ, Banoei MM, Lee CH, Andonegui G, et al. ARDS metabolic fingerprints: characterization, benchmarking, and potential mechanistic interpretation. Am J Physiol Lung Cell Mol Physiol. 2021;321(1):L79-l90.PubMedCrossRef
9.
Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800.PubMedCrossRef
10.
Abdelrahman Z, Li M, Wang X. Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza a respiratory viruses. Front Immunol. 2020;11: 552909.PubMedPubMedCentralCrossRef
11.
Nain Z, Rana HK, Liò P, Islam SMS, Summers MA, Moni MA. Pathogenetic profiling of COVID-19 and SARS-like viruses. Brief Bioinform. 2021;22(2):1175–96.PubMedCrossRef
12.
Grassin-Delyle S, Roquencourt C, Moine P, Saffroy G, Carn S, Heming N, et al. Metabolomics of exhaled breath in critically ill COVID-19 patients: a pilot study. EBioMedicine. 2021;63: 103154.PubMedCrossRef
13.
Bruzzone C, Bizkarguenaga M, Gil-Redondo R, Diercks T, Arana E, Garcia de Vicuna A, et al. SARS-CoV-2 infection dysregulates the metabolomic and lipidomic profiles of serum. iScience. 2020;23(10): 101645.ADSPubMedPubMedCentralCrossRef
14.
15.
Shi D, Yan R, Lv L, Jiang H, Lu Y, Sheng J, et al. The serum metabolome of COVID-19 patients is distinctive and predictive. Metabolism. 2021;118: 154739.PubMedPubMedCentralCrossRef
16.
Lopez-Hernandez Y, Monarrez-Espino J, Oostdam AH, Delgado JEC, Zhang L, Zheng J, et al. Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19. Sci Rep. 2021;11(1):14732.ADSPubMedPubMedCentralCrossRef
17.
Xiao N, Nie M, Pang H, Wang B, Hu J, Meng X, et al. Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications. Nat Commun. 2021;12(1):1618.ADSPubMedPubMedCentralCrossRef
18.
Fraser DD, Slessarev M, Martin CM, Daley M, Patel MA, Miller MR, et al. Metabolomics profiling of critically Ill coronavirus disease 2019 patients: identification of diagnostic and prognostic biomarkers. Crit Care Explor. 2020;2(10): e0272.PubMedPubMedCentralCrossRef
19.
Caterino M, Costanzo M, Fedele R, Cevenini A, Gelzo M, Di Minno A, et al. The serum metabolome of moderate and severe COVID-19 patients reflects possible liver alterations involving carbon and nitrogen metabolism. Int J Mol Sci. 2021;22(17):1.CrossRef
20.
Russell JA, Marshall JC, Slutsky A, Murthy S, Sweet D, Lee T, et al. Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection. BMJ Open. 2020;10(12): e040768.PubMedPubMedCentralCrossRef
21.
Rocheleau GLY, Lee T, Mohammed Y, Goodlett D, Burns K, Cheng MP, et al. Renin-angiotensin system pathway therapeutics associated with improved outcomes in males hospitalized with COVID-19. Crit Care Med. 2022;50(9):1306–17.PubMedPubMedCentralCrossRef
22.
Metwaly S, Côté A, Donnelly SJ, Banoei MM, Lee CH, Andonegui G, et al. ARDS metabolic fingerprints: characterization, benchmarking, and potential mechanistic interpretation. Am J Physiol-Lung Cell Mol Physiol. 2021;321(1):L79–90.PubMedCrossRef
23.
Foroutan A, Fitzsimmons C, Mandal R, Piri-Moghadam H, Zheng J, Guo A, et al. The Bovine Metabolome. Metabolites. 2020;10(6):1.CrossRef
24.
Mohammad Mehdi Banoei CHL, James H et al. Metabolomic profiles in serum predict global functional neurological outcome at 3 and 12 months and death at 3 months following severe traumatic brain injury. 2023.
25.
Gibson PG, Qin L, Puah SH. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med J Aust. 2020;213(2):54–6.PubMedPubMedCentralCrossRef
26.
Mahida RY, Chotalia M, Alderman J, Patel C, Hayden A, Desai R, et al. Characterisation and outcomes of ARDS secondary to pneumonia in patients with and without SARS-CoV-2: a single-centre experience. BMJ Open Respir Res. 2020;7(1): e000731.PubMedCrossRef
27.
Banoei MM, Vogel HJ, Weljie AM, Kumar A, Yende S, Angus DC, et al. Plasma metabolomics for the diagnosis and prognosis of H1N1 influenza pneumonia. Crit Care (Lond, Engl). 2017;21(1):97.CrossRef
28.
Masoodi M, Peschka M, Schmiedel S, Haddad M, Frye M, Maas C, et al. Disturbed lipid and amino acid metabolisms in COVID-19 patients. J Mol Med (Berl). 2022;100(4):555–68.PubMedCrossRef
29.
Navarese EP, Podhajski P, Gurbel PA, Grzelakowska K, Ruscio E, Tantry U, et al. PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection. J Am Coll Cardiol. 2023;81(3):224–34.PubMedPubMedCentralCrossRef
30.
Surma S, Banach M, Lewek J. COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection. Lipids Health Dis. 2021;20(1):141.PubMedPubMedCentralCrossRef
31.
Perła-Kaján J, Jakubowski H. COVID-19 and one-carbon metabolism. Int J Mol Sci. 2022;23(8):1.CrossRef
32.
Adebayo A, Varzideh F, Wilson S, Gambardella J, Eacobacci M, Jankauskas SS, et al. l-Arginine and COVID-19: an update. Nutrients. 2021;13(11):1.CrossRef
33.
Santos AF, Póvoa P, Paixão P, Mendonça A, Taborda-Barata L. Changes in Glycolytic Pathway in SARS-COV 2 Infection and Their Importance in Understanding the Severity of COVID-19. Front Chem. 2021;9:1.CrossRef
34.
35.
Blasco H, Bessy C, Plantier L, Lefevre A, Piver E, Bernard L, et al. The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism. Sci Rep. 2020;10(1):1.CrossRef
36.
Wang Q, Liu D, Song P, Zou M-H. Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. FBL. 2015;20(7):1116–43.PubMed
37.
Valdés A, Moreno LO, Rello SR, Orduña A, Bernardo D, Cifuentes A. Metabolomics study of COVID-19 patients in four different clinical stages. Sci Rep. 2022;12(1):1650.ADSPubMedPubMedCentralCrossRef
38.
Ciccarelli M, Merciai F, Carrizzo A, Sommella E, Di Pietro P, Caponigro V, et al. Untargeted lipidomics reveals specific lipid profiles in COVID-19 patients with different severity from Campania region (Italy). J Pharm Biomed Anal. 2022;217: 114827.PubMedPubMedCentralCrossRef
39.
Banoei MM, Vogel HJ, Weljie AM, Yende S, Angus DC, Winston BW. Plasma lipid profiling for the prognosis of 90-day mortality, in-hospital mortality, ICU admission, and severity in bacterial community-acquired pneumonia (CAP). Crit Care (Lond, Engl). 2020;24(1):461.CrossRef
40.
Lorente JA, Nin N, Villa P, Vasco D, Miguel-Coello AB, Rodriguez I, et al. Metabolomic diferences between COVID-19 and H1N1 influenza induced ARDS. Crit Care. 2021;25(1):390.PubMedPubMedCentralCrossRef
41.
Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611–20.PubMedPubMedCentralCrossRef
42.
Delucchi K, Famous KR, Ware LB, Parsons PE, Thompson BT, Calfee CS, et al. Stability of ARDS subphenotypes over time in two randomised controlled trials. Thorax. 2018;73(5):439–45.PubMedCrossRef
43.
Sinha P, Delucchi KL, McAuley DF, O’Kane CM, Matthay MA, Calfee CS. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med. 2020;8(3):247–57.PubMedPubMedCentralCrossRef
44.
Alipanah-Lechner N, Neyton L, Mick E, Willmore A, Leligdowicz A, Contrepois K, et al. Plasma metabolic profiling implicates dysregulated lipid metabolism and glycolytic shift in hyperinflammatory ARDS. Am J Physiol Lung Cell Mol Physiol. 2023;324(3):L297–306.PubMedCrossRef
Metadata
Title
Using a targeted metabolomics approach to explore differences in ARDS associated with COVID-19 compared to ARDS caused by H1N1 influenza and bacterial pneumonia
Authors
Chel Hee Lee
Mohammad M. Banoei
Mariam Ansari
Matthew P. Cheng
Francois Lamontagne
Donald Griesdale
David E. Lasry
Koray Demir
Vinay Dhingra
Karen C. Tran
Terry Lee
Kevin Burns
David Sweet
John Marshall
Arthur Slutsky
Srinivas Murthy
Joel Singer
David M. Patrick
Todd C. Lee
John H. Boyd
Keith R. Walley
Robert Fowler
Greg Haljan
Donald C. Vinh
Alison Mcgeer
David Maslove
Puneet Mann
Kathryn Donohoe
Geraldine Hernandez
Genevieve Rocheleau
Uriel Trahtemberg
Anand Kumar
Ma Lou
Claudia dos Santos
Andrew Baker
James A. Russell
Brent W. Winston
for the *ARBs CORONA I. Investigators
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2024
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-024-04843-0

Other articles of this Issue 1/2024

Critical Care 1/2024 Go to the issue

Perspective

Stress & strain in mechanically nonuniform alveoli using clinical input variables: a simple conceptual model

Research

Violence against healthcare professionals in intensive care units: a systematic review and meta-analysis of frequency, risk factors, interventions, and preventive measures

Brief Report

Contribution of electrical impedance tomography to personalize positive end-expiratory pressure under ECCO2R

Research

Volatile versus propofol sedation after cardiac valve surgery: a single-center prospective randomized controlled trial

Research

Accuracy of respiratory muscle assessments to predict weaning outcomes: a systematic review and comparative meta-analysis

Research

Incidence, diagnosis, management and outcome of acute mesenteric ischaemia: a prospective, multicentre observational study (AMESI Study)